Literature DB >> 3652514

Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

E N Harris1, A E Gharavi, S P Patel, G R Hughes.   

Abstract

Thirty laboratories from institutions in Britain, France, Italy, The Netherlands, New Zealand, Sweden and the USA participated in a workshop to evaluate the anti-cardiolipin (aCL) test. Participants were asked to measure IgG and IgM aCL in seven samples on each of three separate days. The seven samples were prepared so that IgG and IgM aCL concentrations were known before distribution. Twenty-three of 30 laboratories measuring IgG aCL had significant regression slopes (P less than 0.001) when optical absorbance readings or counts per minute were compared with IgG aCL concentration. Twenty-four of 28 laboratories measuring IgM aCL had significant regression slopes (P less than 0.001). Coefficient of determination (R2) ranged from 81.1% to 98.7% for laboratories with valid IgG aCL assays and from 48.0% to 96.7% for valid IgM aCL assays. Valid assays had in common the use of 10% fetal calf or 10% adult bovine serum in PBS. Assays that were not valid had in common the use of PBS, PBS-Tween, or 0.3% gelatin as diluents. All laboratories with valid assays defined samples with high and moderate aCL levels as positive but there was no consensus about low positive samples. This study shows that properly performed ELISA or SRIA assays can be used to provide an accurate, reproducible, and quantitative measure of IgG and IgM aCL concentration in serum samples.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3652514      PMCID: PMC1542695     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity.

Authors:  C B Colaço; D K Male
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

2.  Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant.

Authors:  D Green; C Hougie; F J Kazmier; K Lechner; P M Mannucci; C R Rizza; Y Sultan
Journal:  Thromb Haemost       Date:  1983-04-28       Impact factor: 5.249

3.  Further immunological studies of sera containing anti-mitochondrial antibodies, type M 5.

Authors:  R Norberg; B Gårdlund; R Thorstensson; K Lidman
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

4.  Lupus anticoagulant in pregnancy.

Authors:  W F Lubbe; W S Butler; S J Palmer; G C Liggins
Journal:  Br J Obstet Gynaecol       Date:  1984-04

5.  Affinity purified anti-cardiolipin and anti-DNA antibodies.

Authors:  E N Harris; A E Gharavi; A Tincani; J K Chan; H Englert; P Mantelli; F Allegro; G Ballestrieri; G R Hughes
Journal:  J Clin Lab Immunol       Date:  1985-08

6.  [Antiphospholipid antibodies, thrombosis and lupus disease. Value of the assay of anticardiolipin antibodies by the ELISA technic].

Authors:  O Meyer; L Cyna; O Borda-Iriarte; P Jungers; J C Piette; M D Dautzenberg; E Dupuy; A Ryckewaert
Journal:  Rev Rhum Mal Osteoartic       Date:  1985-05

7.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

8.  Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.

Authors:  M D Lockshin; M L Druzin; S Goei; T Qamar; M S Magid; L Jovanovic; M Ferenc
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

9.  Obstetric complications associated with the lupus anticoagulant.

Authors:  D W Branch; J R Scott; N K Kochenour; E Hershgold
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

10.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

View more
  97 in total

1.  The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment.

Authors:  M Schwartz; M Rochas; E Toubi; B Sharf
Journal:  J Psychiatry Neurosci       Date:  1999-09       Impact factor: 6.186

2.  Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N J Goulding; M R Podgorski; N D Hall; R J Flower; J L Browning; R B Pepinsky; P J Maddison
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

3.  Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura.

Authors:  Y H Yang; M T Huang; S C Lin; Y T Lin; M J Tsai; B L Chiang
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

4.  Anticardiolipin antibodies in dogs.

Authors:  R Papini; O Pellegrini; C Rossini; G Guidi
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

Review 5.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

6.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

7.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

8.  Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome.

Authors:  Z M Sthoeger; B Tartakovsky; Z Bentwich; E Mozes
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

Review 9.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

10.  Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids.

Authors:  H S Markus; N Hopkinson
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.